Black Diamond Therapeutics, Inc (BDTX)

Etorro trading 970x250
Black Diamond Therapeutics, Inc (BDTX) Logo

About Black Diamond Therapeutics, Inc

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. Address: One Main Street, Cambridge, MA, United States, 02142

Black Diamond Therapeutics, Inc News and around…

Latest news about Black Diamond Therapeutics, Inc (BDTX) common stock and company :

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
08 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass. and NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of preclinical data for three early-stage pipeline programs in oral and poster sessions at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. “Despite clinical advances in precision medicines for patient

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Is Black Diamond Therapeutics, Inc. (BDTX) Going to Burn These Hedge Funds?
04 Oct, 2021 Yahoo! Finance

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
30 Sep, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

How The Parts Add Up: VHT Headed For $289
23 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $289.42 per unit.

Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
21 Sep, 2021 FinancialContent
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform
21 Sep, 2021 FinancialContent
Implied VBR Analyst Target Price: $196
23 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Value ETF (VBR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $195.61 per unit.

Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
12 Aug, 2021 FinancialContent
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors
10 Aug, 2021 FinancialContent
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
04 Aug, 2021 FinancialContent
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
02 Aug, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Is Black Diamond Therapeutics, Inc. (BDTX) A Good Stock To Buy?
29 Jul, 2021 Yahoo! Finance

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of March 31st. The results of that effort will be put on display in this article, as […]

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Look Under The Hood: VTHR Has 10% Upside
22 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 3000 ETF (VTHR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $221.01 per unit.

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
14 Jul, 2021 FinancialContent

Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was ...

The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
14 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
13 Jul, 2021 FinancialContent

Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows. Interesting Highlights: Marqeta ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
08 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

RSI Alert: Black Diamond Therapeutics (BDTX) Now Oversold
07 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
07 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Friday
02 Jul, 2021 FinancialContent

Before 10 a.m. ET on Friday, 43 companies set new 52-week lows. Points of Interest: Autohome (NYSE:ATHM) ...

Black Diamond Therapeutics, Inc (BDTX) is a NASDAQ Common Stock listed in , ,

970x250